GLP-1 Washout: How Long Tirzepatide and Semaglutide Stay in Your System

Why washout timing matters

GLP-1 agonists with long half-lives (semaglutide: ~7 days, tirzepatide: ~5 days) remain pharmacologically active for weeks after the last dose. In most situations this is a feature — once-weekly dosing with sustained effect. But when you need the drug out of your system — for surgery, starting a contraindicated medication, or understanding when effects fade — the long half-life becomes a planning variable.

"Washout" is the period required for a drug to clear to pharmacologically insignificant levels. For GLP-1 agonists, this is typically defined as 5 half-lives from the last dose.

Washout timelines: tirzepatide and semaglutide

These are pharmacokinetic half-lives for the active compound. Actual clinical effects (appetite suppression, gastric emptying delay) may fade before full pharmacokinetic clearance — and may persist longer in some individuals. The 5-half-life window is the standard pharmacokinetic washout definition, not a guarantee that all clinical effects have resolved.

Surgical considerations

The American Society of Anesthesiologists (ASA) issued guidance in 2023 on GLP-1 agonists and anesthesia risk. The primary concern: GLP-1 agonists significantly delay gastric emptying. Standard pre-operative fasting protocols (NPO after midnight) may be insufficient to clear stomach contents in a patient on GLP-1 therapy — increasing aspiration risk during general anesthesia.

The ASA guidance recommended withholding weekly GLP-1 agonists for 1 week before elective procedures under general anesthesia, and daily formulations for 1 day. This was a conservative, practical recommendation; your anesthesiologist and surgeon will have specific guidance for your procedure. Do not make independent decisions about stopping a GLP-1 before surgery — notify your surgical team that you're on a GLP-1 agonist.

Drug interactions requiring washout

Some medications require knowing your GLP-1 status before starting:

• Oral medications with narrow therapeutic windows: GLP-1-mediated gastric emptying delay can alter absorption of oral drugs. For medications where absorption timing matters (some immunosuppressants, thyroid medications, oral contraceptives at specific timing), discuss with your prescribing provider.
• Other GLP-1 or GIP agonists: Switching between GLP-1 agents (semaglutide to tirzepatide) requires a washout period in some protocols to avoid additive effects during the transition window.
• Insulin and other hypoglycemics: GLP-1 agonists reduce blood glucose. Adding or adjusting other glucose-lowering agents requires provider supervision during and after washout.

When appetite suppression fades

Many users experience rapid appetite return within 1–2 weeks of stopping a GLP-1 agonist — often before full pharmacokinetic clearance. This reflects how the appetite-suppressing signal (reduced ghrelin, increased satiety hormone signaling) fades faster than the drug clears in some individuals.

Weight regain during washout is well-documented in trial data: STEP-4 showed significant weight regain within weeks of stopping semaglutide in participants who had achieved maximum weight loss. This is a pharmacological effect of stopping therapy, not a failure of willpower.

Tracking the washout period

The washout clock starts from your last logged injection. My Pep Calc records each dose with timestamp — so the exact date of your last injection is always available, and the half-life chart shows the clearance curve from that date. This is useful for:

• Confirming to a surgical team when you last dosed
• Tracking how many days into washout you are
• Showing your provider the pharmacokinetic picture when restarting after a gap